Clinical trials: Breast Cancer
Breast Cancer
Metformin Hydrochloride in Treating Women With Stage I or Stage II Breast Cancer That Can Be Removed By Surgery
RATIONALE: Metformin hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying how well metformin hydrochloride works in treating women with…
- Trial name
- NCT00984490
- Testing
- metformin hydrochloride, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer, Vaginal Dryness
Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy
It is well documented that women who have breast cancer may experience a decrease in quality of life and sexual functioning due to side effects from adjuvant endocrine therapy, typically aromatase inhibitors (AIs).
- Conditions
- Breast Cancer, Vaginal Dryness, Dyspareunia, Sexual Health Quality of Life
- Trial name
- NCT01697345
- Testing
- Testosterone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Creighton University
Triple Negative Breast Neoplasms
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
- Trial name
- BEGONIA (NCT03742102)
- Testing
- Durvalumab, Capivasertib, Oleclumab
- Where
- 32 sites in United States, Canada and 4 more
- Volunteers
- 243 people
- Sponsor
- AstraZeneca
Bone Loss, Osteoporosis
Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy
Elderly, postmenopausal women with breast cancer on aromatase inhibitors are at increased risk of developing bone loss and osteoporosis.
- Conditions
- Bone Loss, Osteoporosis, Breast Cancer
- Trial name
- REBBeCA II (NCT00485953)
- Testing
- risedronate
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Susan L. Greenspan
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
This phase II trial studies how well anastrozole and letrozole after surgery work in treating patients with stage I-III breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04294225
- Testing
- Anastrozole, Letrozole
- Where
- 3 sites in United States
- Volunteers
- 161 people
- Sponsor
- Mayo Clinic
Breast Cancer
Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer
The primary objective of this study is to determine the safety and feasibility of combining cyclin B1/WT-1/CEF (antigen)-loaded DC vaccination with preoperative chemotherapy.
- Trial name
- NCT02018458
- Testing
- LA TNBC: DC vaccine+Preop chemo, ER+/HER2-BC:DC vaccine+Preop chemo
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor Research Institute
Triple-Negative Breast Cancer
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of magrolimab in combination with nab-paclitaxel or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in…
- Trial name
- ELEVATE TNBC (NCT04958785)
- Testing
- Magrolimab, Nab-Paclitaxel, Paclitaxel
- Where
- 45 sites in United States, Australia and 4 more
- Volunteers
- 92 people
- Sponsor
- Gilead Sciences
Invasive Breast Cancer
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
This study is being done to test the safety and effectiveness of two drugs, Anastrozole and Fulvestrant, used as combined therapy in the neo-adjuvant setting for hormone receptor positive invasive breast cancer.
- Trial name
- NCT00921115
- Testing
- Fulvestrant, Anastrazole
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Kansas Medical Center
Breast Cancer, Breast Neoplasm
Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer
This study will assess the usefulness of a technique called complementary deoxyribonucleic acid (cDNA) microarray-an examination of a wide array of genes to identify disease-associated patterns-for measuring tumor response to…
- Trial name
- NCT00005908
- Testing
- Docetaxel - Dose A, Anastrozole, cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer
This study will define an optimal chemotherapy dose regimen of Myocet in combination with paclitaxel and intravenous Herceptin and will evaluate the efficacy and safety of this dose regimen in patients with metastatic or locally…
- Trial name
- NCT02015676
- Testing
- trastuzumab, paclitaxel, Myocet
- Where
- Spain
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Study of LY573636-sodium in Patients With Metastatic Breast Cancer
The primary purpose of this study is to determine the objective response rate (complete and partial response) for patients who receive LY573636-sodium for metastatic breast cancer.
- Trial name
- NCT00992225
- Testing
- LY573636-sodium
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
MRI-Based Preoperative Accelerated Partial Breast Irradiation
This study examines the feasibility to deliver accelerated partial breast irradiation (APBI) before a lumpectomy is performed. By administering the APBI before the lumpectomy, a smaller volume of breast tissue may be exposed to…
- Trial name
- NCT02728076
- Testing
- Phase II - Preoperative Radiation followed by Lumpectomy.
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Medical College of Wisconsin
Triple Negative Breast Cancer, Triple Negative Breast Neoplasms
Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
This is a single institution, open-label randomized phase 1 trial of neoantigen DNA vaccine alone vs. neoantigen DNA vaccine plus durvalumab in triple negative breast cancer (TNBC) patients following standard of care therapy.
- Conditions
- Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, TNBC - Triple-Negative Breast Cancer, Triple-negative Breast Carcinoma
- Trial name
- NCT03199040
- Testing
- Durvalumab, Neoantigen DNA vaccine, TDS-IM system (Inchor Medical Systems)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Breast Cancer, Neutropenia
Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
This is a randomized, multi-center, single dose, open-label and Neulasta controlled phase 3 study to evaluate the efficacy and safety of F-627 in women with Stage I - III invasive breast cancer receiving chemotherapy treatment.
- Trial name
- NCT03252431
- Testing
- F-627, Neulasta
- Where
- United States
- Volunteers
- 393 people
- Sponsor
- EVIVE Biotechnology
Breast Cancer
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
This is a multicenter run-in phase Ib / roll-over phase II study of triple targeted drug combination (HER2-targeted small molecule inhibitor tucatinib, CDK4/6 inhibitor palbociclib and aromatase inhibitor letrozole) as a first or…
- Trial name
- NCT03054363
- Testing
- Tucatinib in Combination with Palbociclib and Letrozole
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- University of Colorado, Denver
Metastatic Breast Cancer
Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons
Primary Objectives Assess ultrastructure changes in dermal myelinated nerves of patients who receive ixabepilone chemotherapy Detailed characterization of peripheral neuropathy in patients who receive ixabepilone Secondary…
- Trial name
- NCT00627978
- Testing
- ixabepilone
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Weill Medical College of Cornell University
Cancer
Lapatinib in Combination With Vinorelbine
This is a Multicenter, Open-Label, Phase II Study of lapatinib in Combination with Vinorelbine in women with documented evidence of HER2/neu positive breast cancer which is metastatic or recurrent and with or without prior…
- Trial name
- NCT01128543
- Testing
- lapatinib and Vinorelbine
- Where
- 8 sites in Turkey (Türkiye)
- Volunteers
- 29 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain
Many women with breast cancer who are treated with aromatase inhibitor medications develop aches and pains during treatment, and some develop numbness and tingling in their hands and feet.
- Trial name
- NCT01028352
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Michigan Rogel Cancer Center
Breast Cancer
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
The purpose of this study is to collect additional safety and efficacy data for the combination of ribociclib + letrozole in men and pre/postmenopausal women with HR+HER2- advanced breast cancer and no prior hormonal treatment…
- Trial name
- COMPLEEMENT-1 (NCT02941926)
- Testing
- Ribociclib, Letrozole, Goserelin
- Where
- 495 sites in United States, Argentina and 36 more
- Volunteers
- 3,246 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Breast Cancer
Pilot Study Using Molecular Profiling to Find Potential Targets & Select Treatments for Pts With Met br ca
The purpose of this study is to determine the response rate, that is the % of patients with non-progression of their metastatic breast cancer after 4 months on treatment that was selected by molecular testing and proteomics.
- Trial name
- Side-Out (NCT01074814)
- Testing
- Approved therapy will be assigned based on molecular profile and RPMA results
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Translational Drug Development
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.